Tonix plans Phase 2 study of Lyme disease prevention drug TNX-4800

April 29, 2026 7:00 AM

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced plans to initiate a Phase 2 field study of TNX-4800, a monoclonal antibody ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found